2,088
Views
1
CrossRef citations to date
0
Altmetric
Clinical Study

Survival outcomes and adverse events in patients with chronic kidney disease after coronary artery bypass grafting and percutaneous coronary intervention: a meta-analysis of propensity score-matching studies

, ORCID Icon & ORCID Icon
Pages 606-616 | Received 22 Nov 2020, Accepted 08 Mar 2021, Published online: 29 Mar 2021

References

  • Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32(17):2125–2134.
  • Stone GW, Kappetein AP, Sabik JF, et al. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med. 2019;381(19):1820–1830.
  • Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021–2030.
  • Baber U, Farkouh ME, Arbel Y, et al. Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. Eur Heart J. 2016;37(46):3440–3447.
  • Giustino G, Mehran R, Serruys PW, et al. Left main revascularization with PCI or CABG in patients with chronic kidney disease: EXCEL trial. J Am Coll Cardiol. 2018;72(7):754–765.
  • Milojevic M, Head SJ, Mack MJ, et al. The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial. EuroIntervention. 2018;14(1):102–111.
  • Jupiter DC. Propensity score matching: retrospective randomization? J Foot Ankle Surg. 2017;56(2):417–420.
  • Lonjon G, Boutron I, Trinquart L, et al. Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. Ann Surg. 2014;259(1):18–25.
  • Zhang Z, Ni H, Xu X. Do the observational studies using propensity score analysis agree with randomized controlled trials in the area of sepsis? J Crit Care. 2014;29(5):886.e9–886.e15.
  • Syn NL, Kabir T, Koh YX, et al. Survival advantage of laparoscopic versus open resection for colorectal liver metastases: a meta-analysis of individual patient data from randomized trials and propensity-score matched studies. Ann Surg. 2020;272(2):253–265.
  • Gaudino M, Puskas JD, Franco AD, et al. Three arterial grafts improve late survival: a meta-analysis of propensity-matched studies. Circulation. 2017;135(11):1036–1044.
  • Bundhun PK, Bhurtu A, Chen MH. Impact of coronary artery bypass surgery and percutaneous coronary intervention on mortality in patients with chronic kidney disease and on dialysis: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(27):e4129.
  • Doulamis IP, Tzani A, Tzoumas A, et al. Percutaneous coronary intervention with drug eluting stents versus coronary artery bypass graft surgery in patients with advanced chronic kidney disease: a systematic review and meta-analysis. Semin Thorac Cardiovasc Surg. 2020.
  • Wang Y, Zhu S, Gao P, et al. Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: a meta-analysis. Eur J Intern Med. 2017;43:28–35.
  • Baek CH, Kim SO, Park SJ, et al. Propensity-matched comparison of drug-eluting stent implantation and coronary artery bypass graft surgery in chronic hemodialysis patients. J Nephrol. 2014;27(1):87–93.
  • Bangalore S, Guo Y, Samadashvili Z, et al. Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus coronary artery bypass graft surgery. J Am Coll Cardiol. 2015;66(11):1209–1220.
  • Chan W, Ivanov J, Ko D, et al. Clinical outcomes of treatment by percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with chronic kidney disease undergoing index revascularization in Ontario. Circ Cardiovasc Interv. 2015;8(1):e001973.
  • Kilic A, Sultan I, Gleason TG, et al. Surgical versus percutaneous multivessel coronary revascularization in patients with chronic kidney disease. Eur J Cardiothorac Surg. 2020;57(5):994–1000.
  • Komiya T, Ueno G, Kadota K, et al. An optimal strategy for coronary revascularization in patients with severe renal dysfunction. Eur J Cardiothorac Surg. 2015;48(2):293–300.
  • Kumada Y, Ishii H, Aoyama T, et al. Long-term clinical outcome after surgical or percutaneous coronary revascularization in hemodialysis patients. Circ J. 2014;78(4):986–992.
  • Kumada Y, Ishii H, Aoyama T, et al. Long-term clinical outcomes after coronary artery bypass graft versus everolimus-eluting stent implantation in chronic hemodialysis patients. Coron Artery Dis. 2018;29(6):489–494.
  • Lautamäki A, Kiviniemi T, Biancari F, et al. Outcome after coronary artery bypass grafting and percutaneous coronary intervention in patients with stage 3b-5 chronic kidney disease. Eur J Cardiothorac Surg. 2016;49(3):926–930.
  • Marui A, Kimura T, Nishiwaki N, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 2014;114(4):555–561.
  • Roberts JK, Rao SV, Shaw LK, et al. Comparative efficacy of coronary revascularization procedures for multivessel coronary artery disease in patients with chronic kidney disease. Am J Cardiol. 2017;119(9):1344–1351.
  • Sugumar H, Lancefield TF, Andrianopoulos N, et al. Impact of renal function in patients with multi-vessel coronary disease on long-term mortality following coronary artery bypass grafting compared with percutaneous coronary intervention. Internat J Cardiol. 2014;172(2):442–449. doi:10.1016/j.ijcard.2014.01.096.
  • Chang TI, Leong TK, Kazi DS, et al. Comparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease. Am Heart J. 2013;165(5):800–808.e1-2.
  • Vuurmans T, Er L, Sirker A, et al. Long-term patient and kidney survival after coronary artery bypass grafting, percutaneous coronary intervention, or medical therapy for patients with chronic kidney disease: a propensity-matched cohort study. Coron Artery Dis. 2018;29(1):8–16.
  • Doenst T, Haverich A, Serruys P, et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2019;73(8):964–976.
  • Song YB, Lee SY, Hahn JY, et al. Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era. Heart Vessels. 2012;27(5):433–442.
  • Palmerini T, Riva DD, Biondi-Zoccai G, et al. Mortality following nonemergent, uncomplicated target lesion revascularization after percutaneous coronary intervention: an individual patient data pooled analysis of 21 randomized trials and 32,524 patients. JACC Cardiovasc Interv. 2018;11(9):892–902.